Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    03-December-2000      
Issue 234 Next Update - 14:00 UTC 08:00 EST    04-December-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya In Today's Vidyya
An investigational leukemia drug, Glivec, is being heavily cited in journals, abstracts and the press as a possible breakthrough in the treatment of chromosome positive forms of leukemia.

Back To Vidyya Investigational Leukema Drug, Glivec, Featured In More Than 50 Abstracts At The Annual Meeting Of The American Society Of Hematology (ASH)
Novartis Oncology announced that data on Glivec(TM), formerly STI571, was featured in more than 50 abstracts this week at the annual meeting of The American Society of Hematology (ASH) in San Francisco. Glivec is an investigational treatment for certain forms of leukemia. The data offer new and updated information regarding the agent's potential activity in treating certain forms of leukemia that are characterized by the presence of the Philadelphia chromosome, including chronic myeloid leukemia (CML) and, to a lesser extent, acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). More...

Back To Vidyya Abstracts Of Interest - Chronic Myelogenous Leukemia
The postive reports regarding the efficacy of Glivec may cause health professionals to want to review the current knowledge regarding chronic myelogenous leukemia. To help, Vidyya presents a group of citations and abstracts that reflect those newly added to CANCERLIT for the month of November 2000. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms, so you can catch up quickly on your reading in one place. More...

Back To Vidyya Alternative Medicine Watch - Cancer Therapy 714-X
714-X is a controversial cancer treatment. Read a complementary and alternative medicine (CAM) information summary that provides an overview of the use of 714-X as a treatment for cancer in today's issue. The summary includes a brief history of 714-X research; a review of laboratory, animal, and human studies; and possible side effects of 714-X use. 714-X is not approved for use in the US.


Back To Vidyya Information For Patients: Chronic Myelogenous Leukemia
Get easy-to-read information for your patients about CML. According to this NIH patient education handout, chronic myelogenous leukemia (also called CML or chronic granulocytic leukemia) is a disease in which too many white blood cells are made in the bone marrow. The bone marrow is the spongy tissue inside the large bones in the body. The bone marrow makes red blood cells (which carry oxygen and other materials to all tissues of the body), white blood cells (which fight infection), and platelets (which make the blood clot). More...

Back To Vidyya

December Is National Drunk And Drugged Driving Prevention Month
December has been designated National Drunk and Drugged Driving Prevention Month by the National Drunk and Drugged Driving Prevention Month Coalition, a national public-private partnership devoted to preventing impaired driving crashes. During 1999, alcohol-related motor-vehicle crashes resulted in an estimated 15,786 deaths in the United States (National Highway Traffic Safety Administration [NHTSA], unpublished data, October 2000). More...

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.